Agios Pharmaceuticals
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139
Phone: (617) 649 8600Website: https://www.agios.com/Careers: www.agios.com/careers/our-values
Latest news
- FDA Approves Pyrukynd (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
17 February 2022 - Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
17 August 2021 - Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
21 June 2021 - Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
8 December 2019
Drugs Associated with Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Idhifa
Generic name: enasidenib Drug class: miscellaneous antineoplastics |
||
|
Pyrukynd
Generic name: mitapivat Drug class: miscellaneous metabolic agents |
||
|
Tibsovo
Generic name: ivosidenib Drug class: miscellaneous antineoplastics |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||